The epidemiology of inflammatory bowel disease (IBD) has undergone considerable shifts
since its emergence in the Western world over a century ago, especially in the last few …

Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

Outcomes for patients starting a new treatment for inflammatory bowel disease are
characterized by uncertainty of treatment response. Although it is natural to hope that new …

Inflammatory bowel disease (IBD) management has changed dramatically over the past 20
years, after the introduction of targeted biological therapies. However, the impact of these …

Abstract Background and Aims Inflammatory bowel disease (IBD) can lead to long-term
complications that significantly impact patients' quality of life and healthcare resource …

Summary Background 5‐aminosalicylates (5‐ASA) are widely used in Crohn's disease (CD)
despite guidelines advising otherwise. We aimed to assess in nationwide study the …

In the 1990s, tumour necrosis factor-α inhibitor therapy ushered in the biologic therapy era
for inflammatory bowel disease, leading to marked improvements in treatment options and …

Inflammatory bowel disease (IBD) is a group of chronic diseases that includes ulcerative
colitis, Crohn's disease, and indeterminate colitis. Patients with IBD require prolonged …

Growing evidence shows that ulcerative colitis (UC) is a progressive disease similar to
Crohn's disease (CD). The UC-related burden is often underestimated by physicians and a …

The production of paediatric pharmaceutical forms represents a unique challenge within the
pharmaceutical industry. The primary goal of these formulations is to ensure therapeutic …